Oramed Pharmaceuticals Inc ORMP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ORMP is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.27
- Day Range
- $2.25–2.40
- 52-Week Range
- $1.67–5.25
- Bid/Ask
- $2.20 / $2.47
- Market Cap
- $94.41 Mil
- Volume/Avg
- 59,529 / 162,103
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 66.60
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
- Website
- https://www.oramed.com
Comparables
Valuation
Metric
|
ORMP
|
ENTA
|
AVIR
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.54 | 1.48 | 0.55 |
Price/Sales | 66.60 | 3.83 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ORMP
ENTA
AVIR
Financial Strength
Metric
|
ORMP
|
ENTA
|
AVIR
|
---|---|---|---|
Quick Ratio | 3.05 | 6.04 | 17.86 |
Current Ratio | 3.06 | 6.25 | 18.24 |
Interest Coverage | −0.44 | — | — |
Quick Ratio
ORMP
ENTA
AVIR
Profitability
Metric
|
ORMP
|
ENTA
|
AVIR
|
---|---|---|---|
Return on Assets (Normalized) | −4.98% | −27.96% | −15.46% |
Return on Equity (Normalized) | −6.04% | −47.34% | −16.16% |
Return on Invested Capital (Normalized) | −8.54% | −44.45% | −19.92% |
Return on Assets
ORMP
ENTA
AVIR
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Npgjrpwc | Rvfwn | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xstfcbwc | Fhbtkc | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dpnymhq | Jmpnvty | $98.8 Bil | |
MRNA
| Moderna Inc | Hqwhryvx | Kqry | $38.8 Bil | |
ARGX
| argenx SE ADR | Bgvllmnd | Gyn | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Vnmcfphk | Blb | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ktxsdvxf | Kzctl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dzfbsqbs | Ytkjzrk | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bbzcjnsxqw | Nxgmcc | $12.4 Bil | |
INCY
| Incyte Corp | Mzssxhhgx | Bggtvvk | $11.9 Bil |